AI Article Synopsis
- - Fibrosis, which involves the activation of fibroblasts and the buildup of extracellular matrix, is a key issue in many cardiovascular diseases and is tough to treat effectively.
- - Researchers Rurik et al. reported a new method using modified mRNA technology to transform T cells in mice into specialized CAR-T cells that can target and eliminate fibroblasts.
- - This innovative immunotherapy approach shows promise for developing treatments aimed at addressing fibrosis in cardiovascular conditions.
Article Abstract
Fibrosis, or chronic fibroblast activation and extracellular matrix deposition, underlies most cardiovascular diseases and remains challenging to target therapeutically. Reported in Science by Rurik et al., modified mRNA technology can reprogram endogenous T cells into fibroblast-ablating CAR-Ts in mouse hearts, offering a promising and tractable immunotherapy approach for tackling fibrosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.stem.2022.02.002 | DOI Listing |
Publication Analysis
Top Keywords
cell immunotherapy
4
immunotherapy cardiac
4
cardiac fibrosis
4
fibrosis mrna
4
mrna starts
4
starts car
4
car fibrosis
4
fibrosis chronic
4
chronic fibroblast
4
fibroblast activation
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!